Sanofi and Regneron prep their cardio contender for FDA review after a Phase III sweep

Damian Garde

and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew III trials in which the drug slashed patients' bad cholesterol.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS